Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 9/20 | 0.65 |
| ▸ | HTR2A | P28223 | 6/20 | 0.52 |
| ▸ | HTR2C | P28335 | 6/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3162019 | 0.84 | HSD11B1 (0.48) | NFE2L2HTR2AHTR2CKCNH2PTGS1 | |
| SCHEMBL4014968 | 0.82 | NFE2L2 (0.65) | NFE2L2HTR2AHTR2CKCNH2PTGS1 | |
| SCHEMBL4014974 | 0.82 | NFE2L2 (0.65) | NFE2L2HTR2AHTR2CKCNH2PTGS1 | |
| SCHEMBL13790315 | 0.82 | NFE2L2 (0.96) | NFE2L2HTR2AHTR2CKCNH2PTGS1 | |
| SCHEMBL21030098 | 0.80 | NFE2L2 (1.00) | NFE2L2HTR2AHTR2CKCNH2PTGS1 | |
| SCHEMBL20995877 | 0.74 | NFE2L2 (1.00) | NFE2L2HTR2AHTR2CKCNH2PTGS1 | |
| SCHEMBL20995870 | 0.74 | NFE2L2 (1.00) | NFE2L2HTR2AHTR2CKCNH2PTGS1 | |
| SCHEMBL723353 | 0.73 | NFE2L2 (0.78) | NFE2L2HTR2AHTR2CKCNH2PTGS1 | |
| SCHEMBL723352 | 0.73 | NFE2L2 (0.78) | NFE2L2HTR2AHTR2CKCNH2PTGS1 | |
| SCHEMBL1755404 | 0.73 | NFE2L2 (0.78) | NFE2L2HTR2AHTR2CKCNH2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170824-A1 | Diarylsulfones as 5-HT2A Antagonists | CASTRO PINEIRO JOSE LUIS | 2009-07-02 | — | — | US | disclosed |
| EP-1858852-B1 | HETEROARYLSULFONYL STILBENES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2009-07-01 | — | — | EP | disclosed |
| US-7468393-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME LTD. (GB) | 2008-12-23 | — | — | US | disclosed |
| US-20080280956-A1 | Heteroarylsulfonyl Stilbenes as 5-Ht2a Antagonists | GILLIGAN MYRA | 2008-11-13 | — | — | US | disclosed |
| EP-1858852-A1 | HETEROARYLSULFONYL STILBENES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2007-11-28 | — | — | EP | disclosed |
| US-20070203205-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| US-7217740-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP AND DOHME | 2007-05-15 | — | — | US | disclosed |
| WO-2006095205-A1 | HETEROARYLSULFONYL STILBENES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203205-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | NFE2L2 3662/4885HTR2A 1/4885HTR2C 4/4885 |
| US-20080280956-A1 | Heteroarylsulfonyl Stilbenes as 5-Ht2a Antagonists | HTR2A, HTR2B, HTR2C | NFE2L2 2791/4885HTR2A 1/4885HTR2C 3/4885 |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | NFE2L2 3662/4885HTR2A 1/4885HTR2C 4/4885 |
| US-20090170824-A1 | Diarylsulfones as 5-HT2A Antagonists | HTR2A, HTR2B, HTR1A | NFE2L2 3662/4885HTR2A 1/4885HTR2C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.